title: Hearing loss and glutamate efflux in the perilymph following transient hindbrain ischemia in gerbils.
abstract: The mechanism underlying ischemia-induced hearing loss was studied in gerbils with transient hindbrain ischemia. Occlusion of the vertebral arteries caused an increase in the concentration of glutamate in the perilymph and elevated the compound action potential (CAP) threshold to 24.6 dB at 5 minutes. the CAP threshold subsequently recovered on reperfusion, gradually reaching 8.3 dB 120 minutes after reperfusion. Under electron microscopy, afferent dendrites of the cochlear nerve in contact with inner hair cells exhibited abnormal swelling 5 minutes after ischemia/reperfusion. These morphological changes were not observed in cochleas treated with an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate-type glutamate receptor antagonist, 6-7-dinitroquinoxaline-2,3-dione (DNQX), before hindbrain ischemia; an N-methyl-D-aspartate (NMDA)-type receptor antagonist, D-2-amino-5-phosphonopentanoate (D-AP5), was ineffective. Moreover, the histopathological alterations noted 5 minutes after reperfusion were spontaneously ameliorated 120 minutes after ischemia/reperfusion. These findings suggest that the ischemia-induced increase in extracellular glutamate concentration with subsequent activation of AMPA/kainate receptors is responsible for neurite degeneration and hearing loss in the early stages following transient hindbrain ischemia.
authors.affiliation: Department of Otolaryngology, Ehime University School of Medicine, Japan. hakubax@m.ehime-u.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Hakuba
authors.forename: K
authors.initials: K
authors.lastname: Koga
authors.forename: M
authors.initials: M
authors.lastname: Shudou
authors.forename: F
authors.initials: F
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Mitani
authors.forename: K
authors.initials: K
authors.lastname: Gyo
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000818:Animals; D001300:Audiometry, Evoked Response; D002560:Cerebrovascular Circulation; D003056:Cochlear Nerve / Q000473:pathology; D003638:Deafness / Q000209:etiology* / Q000503:physiopathology; D003712:Dendrites / Q000648:ultrastructure; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005849:Gerbillinae / Q000502:physiology*; D018698:Glutamic Acid / Q000378:metabolism*; D002546:Ischemic Attack, Transient / Q000150:complications* / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D010498:Perilymph / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology; D012249:Rhombencephalon / Q000098:blood supply
chemical_list: D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018698:Glutamic Acid; C056723:FG 9041; D015763:2-Amino-5-phosphonovalerate